Nateglinide – 250 mg

Brand:
Cayman
CAS:
105816-04-4
Storage:
-20
UN-No:
Non-Hazardous - /

Nateglinide is a hypoglycemic agent.{38370,38371,38372} It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 μM.{38370} Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic β cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine (Item No. 17549). Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide (Item No. 14576). Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice.{38371} It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{38372} Formulations containing nateglinide have been used in the treatment of type 2 diabetes.  

 

Available on backorder

SKU: 23320 - 250 mg Category:

Description

A hygoglycemic agent; induces insulin and somatostatin release from perfused rat pancreas from 0.03-3 μM; increases intracellular calcium levels in isolated rat pancreatic β cells at 3 μM; reduces blood glucose levels by 20% in fasted mice at 1.6 mg/kg orally; decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and an STZ-induced rat models of diabetess,


Formal name: N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine

Synonyms:  A-4166|SDZ-DJN 608

Molecular weight: 317.4

CAS: 105816-04-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ion Channel Modulation||Research Area|Endocrinology & Metabolism|Hormones & Receptors||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes